Bristol-Myers submits NDAs for Hep C drugs

|About: Bristol-Myers Squibb C... (BMY)|By:, SA News Editor

Bristol-Myers Squibb (BMY +0.2%) submits new drug applications to the FDA for its NS5A replication complex inhibitor daclatasvir (DVC) and its NS3 protease inhibitor asunaprevir (ASV) for the treatment of Hepatitis C.

The regulatory agency recently designated the drugs Breakthrough Therapies.

The European Medicines Agency and Japan's Pharmaceutical and Medical Devices Agency are also reviewing the products under accelerated processes.